<乌鸦传媒>Rechallenge With PARP Inhibitor Slows Relapsed Ovarian Cancer Benefits platinum-sensitive disease irrespective of BRCA, homologous repair status, study showed Sep 17, 2021
<乌鸦传媒>Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too! A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021
<乌鸦传媒>COVID Vaccine Protection; 'Until You Die From the Cancer'; What's Palliative Care? News, features, and commentary about cancer-related issues Jun 10, 2021
<乌鸦传媒>Ovarian Cancer Screening Trial Still Sees No Death Reduction Researchers "disappointed" by long-term results of U.K. study of 200,000 postmenopausal women May 22, 2021
<乌鸦传媒>Report: Worst Hospitals for Unnecessary Procedures Lown Institute says report is the first to name hospitals with high rates of overuse May 04, 2021
<乌鸦传媒>Triage System Gets High Marks for Ovarian Cancer Debulking Surgery Key factors predicted threefold higher risk of 90-day mortality with primary surgery Mar 26, 2021
<乌鸦传媒>HIPEC Combo Doubles PFS in Advanced Ovarian Cancer Cisplatin/paclitaxel boosts outcomes without increasing complications in registry study Mar 26, 2021
<乌鸦传媒>Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer Ixabepilone plus bevacizumab yielded responses in a third of patients Mar 26, 2021
<乌鸦传媒>Androgen Receptor Inhibitor Active in Endometrial Cancer SGO: Apatinib for platinum-resistant ovarian cancer, pembrolizumab for advanced vulvar cancer Mar 22, 2021
<乌鸦传媒>Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer Responses in 37% of patients with AVB-500, higher without prior bevacizumab Mar 21, 2021
<乌鸦传媒>Is MIS Viable for Interval Debulking in Ovarian Cancer? Retrospective study compared approach versus open surgery after neoadjuvant chemotherapy Mar 21, 2021
<乌鸦传媒>PARP Inhibitor Tops Chemo for Recurrent BRCA Ovarian Cancer Modest improvement in PFS with rucaparib but worse outcome for reversion mutation Mar 20, 2021
<乌鸦传媒>New Targeted Therapies Show Promise in Cancer Selected abstracts from the ESMO Targeted Anticancer Therapies virtual meeting Mar 03, 2021
<乌鸦传媒>Kardashian Makeup Artist Hrush Achemyan's Ovarian Cancer Beauty influencer reveals diagnosis Jan 21, 2021
<乌鸦传媒>PARP Inhibitors Linked With Blood Cancer Risk Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden Dec 28, 2020
<乌鸦传媒>Immunotherapy Falls Short Again in Ovarian Cancer No PFS benefit in advanced disease with addition of atezolizumab to chemo, bevacizumab Sep 23, 2020
<乌鸦传媒>Which Women Choose Hormones for Surgical Menopause? Understanding patterns of use can help improve targeting for education and counseling, researchers say Aug 12, 2020
<乌鸦传媒>Second Surgery Gets OS Win in Recurrent Ovarian Cancer Survival improved by nearly 8 months with cytoreductive surgery at first relapse Jun 02, 2020
<乌鸦传媒>Avelumab Flops Again in Ovarian Cancer Another negative phase III trial, now in the first-line setting May 19, 2020
<乌鸦传媒>PARP Inhibitors Still Work in HRD-Low Ovarian Cancer In VELIA, homologous recombination deficiency score prognostic but not predictive May 14, 2020
<乌鸦传媒>KRAS May Predict Benefit of MEK Inhibitors in Some Ovarian Cancers Nearly 7-month PFS boost in patients with KRAS mutations May 11, 2020
<乌鸦传媒>New Standard in Recurrent, Platinum-Sensitive Ovarian Cancer Pegylated liposomal doxorubicin unseats gemcitabine in standard platinum regimen Apr 21, 2020
<乌鸦传媒>Breastfeeding Tied to Lower Ovarian Cancer Risk Lower incidence of borderline tumors as well Apr 02, 2020
<乌鸦传媒>Post-Op HPV Vaccine Cuts Cervical Precancer Recurrences Plus osteoporosis in gynecologic cancer survivors, and a novel approach to CIN2/3 Mar 31, 2020
<乌鸦传媒>DOAC Works in Cancer-Related VTE, No Tradeoff in Bleeds Apixaban monotherapy matches dalteparin in non-inferiority trial Mar 29, 2020
<乌鸦传媒>After Five Months in a Coma, Young Nurse Wakes Up Chicago RN with rare autoimmune encephalitis responds to unusual treatment Jan 10, 2020
<乌鸦传媒>Trametinib Tx Shows Promise in Tough-to-Treat LGSOC Targeted drug provokes good response in chemoresistant, low-grade serous ovarian or peritoneal cancer Sep 30, 2019
<乌鸦传媒>Data Support 'Best Drug First' in EGFR-Mutant NSCLC Six-month survival gain with osimertinib, adding to PFS, safety advantages Sep 29, 2019
<乌鸦传媒>PARP Inhibitors: The Key to a Tx Paradigm Shift in Ovarian Ca? PRIMA and VELIA trial findings advance niraparib and veliparib to the therapeutic front lines Sep 29, 2019
<乌鸦传媒>First-Line Combo Boosts PFS in Advanced Ovarian Ca Olaparib-bevacizumab maintenance boosts PARP inhibitor benefits beyond BRCA-mutated subgroup Sep 28, 2019
<乌鸦传媒>Obamacare Cut Racial Disparities in Cancer Care Time to cancer treatment evens in blacks and whites with Medicaid expansion Jun 03, 2019
<乌鸦传媒>Birth Control Pills Tied to Reduced Risk of Deadly Ovarian Ca Every 5 years of use linked with 32% reduction in risk of dying within 12 months of diagnosis Apr 04, 2019 video
<乌鸦传媒>Early Data Send Strong Signal in Advanced Gyn Cancers Clinical benefit rate tops 90% in pair of single-center studies Mar 19, 2019
<乌鸦传媒>'End of the Road' for Trabectedin in Ovarian Cancer? Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations Mar 19, 2019
<乌鸦传媒>When PARP Inhibitors Fail in Ovarian Cancer Study identifies subgroup for whom another go could be worthwhile Mar 18, 2019
<乌鸦传媒>Avelumab Combo Falls Short in Advanced Ovarian Ca But showed promise in PD-L1-positive group Mar 18, 2019
<乌鸦传媒>PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Ca Analysis attempts to quantify patients' quality of survival Mar 17, 2019
<乌鸦传媒>Lymphadenectomy Often Useless in Ovarian Cancer No survival benefit with normal nodes after complete macroscopic resection Mar 01, 2019
<乌鸦传媒>Does Johnson's Baby Powder Cause Cancer? Milton Packer says the $4.69-billion verdict is about anger, not medicine Jan 09, 2019
<乌鸦传媒>Simple Ovarian Cysts Hold No Cancer Risk Malignancy extremely rare, don't need surveillance Nov 12, 2018
